baber/WOPTO huggingface dataset:
Patent NZ-521498-A (NZ)
Title: Protective cover for vaccine container
Inventor: LLOYD JOHN SANDERSON
IPC: B65D81/18
Filed: 2002-09-20
Abstract: A vaccine bag (broken outline 11) held within a strapless protective cover (12) and retained with the cover by a Velcro fastener flap (13). An opening (14) in the bottom of the bag enables an administration tube (15) to pass through the pouch and travel up to the hand-held administration gun (16). The bag includes a neck sling (17) so that the bag may be used with the sling passing either side of the flap. The flap prevents the bag's sliding movement when supported by the neck sling thereby making sure the bag is covered.
Patent NZ-527634-A (NZ)
Title: Means and methods for synoviocyte cell transduction
Inventor: VOGELS RONALD
IPC: C12N15/861
Filed: 2000-03-03
Abstract: Disclosed is a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism synoviocytes, wherein the capsid of the adenoviral vector comprises at least the knob domain of the fiber protein of adenovirus serotype 35. Disclosed also are methods for the treatment of diseases, preferably joint related diseases.
Patent NZ-530768-A (NZ)
Title: Container washing apparatus
Inventor: MACDONALD RONALD ANTHONY
IPC: B08B9/30
Filed: 2002-07-26
Abstract: Disclosed is a transport container adapted to wash the outside of a transport container, excluding washing vehicles, the apparatus comprising at least two sprayer units and a rotating sprayer unit. (62) Divided out of 512650
Patent NZ-531551-A (NZ)
Title: Hydrophilic polymers and their use as membranes in electrochemical cells
Inventor: HIGHGATE DONALD JAMES
IPC: C25B9/23
Filed: 2002-09-09
Abstract: A hydrophilic cross-linked polymer obtained by copolymerisation of hydrophobic and hydrophilic monomers that give a cross-linked hydrophilic polymer on polymerisation; a monomer including a strongly ionic group; and water is disclosed. These polymers are electrically conducting and are suitable for membranes in an assembly that can be used in electrolysers and electrochemical cells, e. g. fuel cells. More generally, a membrane electrode assembly comprises electrodes and an ion-exchange membrane which comprises a hydrophilic polymer obtained by copolymerisation of hydrophobic and hydrophilic monomers that give a cross-linked hydrophilic polymer on polymerisation; a monomer including a strongly ionic group; and water. Also disclosed is a method for producing a membrane electrode assembly comprising electrodes and an ion-exchange membrane, comprises introducing between the electrodes a material or materials from which the membrane can be formed, and forming the membrane in situ.
Patent NZ-531886-A (NZ)
Title: Lock device and a plate element comprised therein
Inventor: HIRVI JORMA
IPC: E05B9/02
Filed: 2002-09-25
Abstract: A lock device comprises a plate element having a face plate and a beam attached to the face plate. The face plate is provided with apertures for at least one bolt. A lock housing is mounted to the plate element and includes a lock mechanism. At least one lock bolt is mounted to the plate element and is arranged for movement between an extended and a retracted position. When retracted, the bolt is sideways essentially surrounded by the beam, which preferably has a U-shaped cross-section. A driving element is mechanically connected to the bolt and is arranged to be actuated by the lock mechanism. The bolts including the driving arrangement thereof are thereby protected from damage, particularly if the plate element comprises high-strength material. The integration of front functions in the plate element allows for a modularisation of the lock device and thereby fewer parts for stock-keeping and/or a wider range of possible lock devices.
Patent NZ-539138-A (NZ)
Title: Transaction processing system
Inventor: BOYLAN JONATHAN
IPC: G06F9/40
Filed: 2003-09-23
Abstract: A processor (2) in a transaction processing system (1) has an event engine and a scenario engine. The event engine stores a framework (20) for each entity or type of service. The framework (20) has a parent class (21) and subsidiary classes (22-27). In real time the event engine instantiates an event object from a relevant class (22-27), giving it an effective time on a timeline of the parent class (21). The event objects may subsequently be handled as autonomous units for generation of reports or batch processing. The event engine moves the event objects between states of a finite state machine. A scenario engine also manipulates objects according to a finite state machine with future dates as the effective times. There is a state transition from the scenario environment to the event engine (live) environment.
Patent NZ-541730-A (NZ)
Title: Apparatus for preparing a rolled food product, particularly sushi
Inventor: TATHAM WARREN
Filed: 2005-08-10
Abstract: An apparatus for preparing a rolled food product, particularly sushi, the apparatus comprising: (i) a hollowed container having a fixed partially closed end and an open end, the closed end having recesses forming an aperture about its centre, the container being separable, in an open position, such that a plurality of cavities is formed, the cavities being adapted to accommodate food material, and (ii) a rod or piston means configured to fit the recesses or aperture and for its suitability to compress the food product to form a roll having a desired consistency. (61) Addition to 525862
Patent NZ-542092-A (NZ)
Title: Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime
Inventor: GOLD MICHAEL
IPC: A61P9/10
Filed: 2004-03-26
Abstract: Disclosed is the use of EPO in promoting patient recovery following an ischemic event wherein EPO is formulated for administration according to a dosage regime wherein a first dose of EPO is delivered during a period from 8-26 hours after the ischemic event followed by a second dose of EPO delivered within 8-26 after the first dose.
Patent NZ-542454-A (NZ)
Title: Photoelectrochemical determination of chemical oxygen demand
Inventor: ZHAO HUIJUN
IPC: G01N27/30
Filed: 2004-04-05
Abstract: A method for determining chemical oxygen demand of a water sample comprises the steps of (a) applying a constant potential bias to a photoelectrochemical cell, having a photoactive working electrode and a counter electrode, and containing a supporting electrolyte solution; (b) illuminating the working electrode with a light source and recording the background photocurrent produced at the working electrode from the supporting electrolyte solution; (c) adding a water sample, to be analysed, to the photoelectrochemical cell; (d) illuminating the working electrode with a light source and recording the total photoelectrocurrent produced with the sample; (e) determining the chemical oxygen demand according to the type (exhaustive or non-exhaustive) of degradation conditions employed.
Patent NZ-543741-A (NZ)
Title: Substituted pyrrole derivatives and their use as HMG-Co inhibitors
Inventor: SALMAN MOHAMMAD
IPC: C07D207/00
Filed: 2004-05-28
Abstract: Disclosed are substituted pyrrole derivatives of formula I, their pharmaceutically acceptable salts (suitable salts include salts selected from lithium, sodium, potassium, calcium, magnesium, zinc, aluminium, amino acid, ammonium, mono-alkyl ammonium, dialkyl ammonium, trialkyl ammonium and N-methyl glucamine), pharmaceutically acceptable solvates, tautomers, racemates, pure enantiomers, polymorphs, diastereoisomers or N-oxides, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Of particular importance is the compound which is (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid. Also disclosed is the use of a compound as defined above for the manufacture of a medicament for treatment or prevention of cholesterol-related disease, diabetes and related diseases, cerebrovascular disease or cardiovascular disease, in a mammal (and particularly diseases such arteriosclerosis, atherosclerosis, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypertension, stroke, ischemia, endothellium dysfunctions, peripheral vascular disease, peripheral arterial disease, coronary heart disease, myocardial infarction, cerebral infarction, myocardial microvascular disease, dementia, Alzheimer's disease, osteoporosis and/or osteopenia, angina or restenosis). A process for the preparation of the above compounds is further disclosed.
Patent NZ-543792-A (NZ)
Title: An isloated DNA molecule encoding a canine GHRH gene and polypeptides woth the ability to stimulate growth hormone secretion
Inventor: FISCHER LAURENT BERNARD
IPC: C12N15/12
Filed: 2004-05-03
Abstract: Disclosed is a canine pre-proGHRH polypeptide and an isolated polynucleotide which encodes the canine pre-proGHRH. Also disclosed are vectors encoding and expressing the canine pre-proGHRH which can be used to treat disease and growth hormone deficiencies by gene therapy, particularly in dogs.
Patent NZ-545680-A (NZ)
Title: Identification document with lenticular watermark
Inventor: MERRY TREVOR
Filed: 2006-03-03
Abstract: The invention relates to the field of identification documents and more particularly to an identification document with enhanced security features. An identification document (10) and method of making such a document is disclosed comprising a transparent window (16) which incorporates micro printing and lenticular technology to record document bearer specific information on a microscopic and macroscopic level. A window (16) is punched into an opaque layer (18), respective laser engravable synthetic transparent layers (20,22) are laminated to opposing sides of the opaque layer (18), and respective protective synthetic transparent layers (24,26) are laminated to the outer sides of the two laser engravable synthetic transparent layers. A lenticular array (28) is then formed on the front of the window in the associated protective synthetic transparent layer and then document bearer specific information is micro printed using a laser inscribing into the rear of the window in the laser engravable synthetic transparent layers. The phase shifted image is comprised of alphanumeric characters which are readable with the aid of a magnifying device, but which are also arranged to form a macroscopic lenticular image viewable through the lenticular array. Both the microscopic and macroscopic information can be readily compared with identical data printed on the identification document to authenticate the identification document and/or document bearer.
Patent NZ-546098-A (NZ)
Title: Dryer, drying method and drying plant
Inventor: WILSON DAVID
IPC: F26B21/08
Filed: 2004-09-24
Abstract: A dryer for drying particulate material is disclosed. The dyer includes at least one substantially vertical elongate container having an upper inlet and a lower outlet. The upper inlet receives a charge of moisture containing particulate material and the lower outlet discharges dried particulate material, where the particulate material travels under the influence of gravity from the inlet to the outlet. Also provided are two substantially vertical and opposed gas permeable walls through which a drying gas can pass to contact the particulate material. The dryer also includes plenums on exterior surfaces of the gas permeable walls, covering ingress and egress openings within the gas permeable walls, wherein the plenums are divided into zones of differing air stream properties.
Patent NZ-551044-A (NZ)
Title: A method for the preparation of dicarboxylic imides from a dicarboxylic anhydride and urea or a urea derivative
Inventor: LANDMESSER THOMAS
Filed: 2006-11-03
Abstract: A method for the preparation of a dicarboxylic imide having the general formula (I) R1-(CO)-(NR3)-(CO)-R2  is disclosed, wherein the method comprises: - providing a urea or urea derivative of the form (R3NH)-(CO)-(NR3H); - adding the urea or urea derivative to a solvent containing a dicarboxylic anhydride having the general formula (II) R1-(CO)-O-(CO)-R2 to react the anhydride with the urea or urea derivative in the solvent to form a dicarboxylic imide of (I); wherein the solvent is pre-heated to a temperature to facilitate the reaction of the anhydride with the urea or urea derivative prior to addition of the urea or urea derivative to the solvent; and wherein R1, R2 and R3 independently of one another can be substituted or unsubstituted, unbranched or branched or cyclic C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C4-C10 aryl, C4-C10 heteroaryl, or wherein R1 and R2 can be bound to each other to form a ring, and/or wherein R3 can also be H.
Patent NZ-551733-A (NZ)
Title: Piperazinediones as oxytocin receptor antagonists
Inventor: BORTHWICK ALAN DAVID
IPC: C07D401/06
Filed: 2005-06-21
Abstract: Disclosed is a compound of formula (I), wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, and R4 and R5 are either separate substituents as described in the specification or joined to form morpholino. Also disclosed is a process for preparing the above compound, and its use in treating pre-term labour, dysmenorrhea, endometrosis, or benign prostatic hyperplasia.
Patent NZ-552049-A (NZ)
Title: Orthopaedic implant with sensors
Inventor: MORGAN CHAD
IPC: A61F2/30
Filed: 2005-06-07
Abstract: The present disclosure relates to an orthopaedic implant, such as a bone plate, for the fixation of bone where the implant also has at least one microchip and at least one sensor connected to the microchip. The sensor or sensors are configured to receive physical stimulus from a portion of the implant or the patient's tissue such as temperature, pressure, and strain. The information received from the sensor or sensors is gathered by the microchip and transmitted to a receiver, such as a personal computer, outside the patient. This information enables doctors to diagnose the useful life of the implant, the load sharing of the bone plate, and possible complications typically associated with orthopaedic implants such as infection, fracture non-union, and fatigue.; The implant may also have one or more electrodes located on its surface which emit an electric current to stimulate healing of the broken or fractured bone.
Patent NZ-556120-A (NZ)
Title: Mounting slide insert set and method for use in a guide shoe of a lift installation that cleans and maintains a smoth surface of the guide rails during construction, that is then replaced for normal operation
Inventor: ACH ERNST
Filed: 2007-06-26
Abstract: A mounting set for mounting on a lift cage (14) of a lift installation is disclosed. The mounting set comprises of at least one guide shoe (12), at least one standard slide insert (3) with standard slide zone, at least one mounting slide insert (13) with mounting slide zone. The mounting slide zone of the mounting slide insert (13) consists of a material different from that of the standard slide zone of the standard slide insert. The material of the mounting slide zone has a greater hardness than the material of the guide rail (11). The material and surface configuration of the mounting slide zone of the mounting slide insert (13) is selected so that during movement of the lift cage (14), along the guide rail (11) of the lift installation, a cleaning action at the guide rail (11) results. The mounting slide insert (13) is for temporary use during construction and is replaced by the standard slide insert (3) for normal operation.
Patent NZ-565128-A (NZ)
Title: Form for casting light weight composite concrete panels
Inventor: SMITH BRIAN D
IPC: B28B7/02
Filed: 2006-06-23
Abstract: A concrete form for supporting a steel frame above a pouring pad comprises a vertical wall configured to be fastened to the steel frame, a marker on the vertical wall for spacing the frame a predetermined distance above the pouring pad, and a sealing member extending from a lower edge of the wall for sealing the form to the pouring pad. Preferably, the vertical wall has an upper portion, a horizontally offset lower portion, and a shoulder there between which engages an edge of the steel frame. The sealing member is preferably a lip extending from the vertical wall at an obtuse angle and engaging the pouring pad at an obtuse angle.
Patent NZ-566104-A (NZ)
Title: Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules - SEQ ID NO: 43
Inventor: DENGJEL JORN
IPC: A61K39/00
Filed: 2006-09-05
Abstract: Disclosed are immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to a novel peptide sequence, SEQ ID NO:43, derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Patent NZ-567440-A (NZ)
Title: Detection of ApoA1 in urine to detect transitional cell carcinoma of the bladder
Inventor: SOLOAGA VILLOCH ANA
IPC: G01N33/68
Filed: 2006-10-10
Abstract: A method for detecting the presence of transitional cell carcinoma of the bladder that includes: (a) Detecting and quantifying the biomarker A-1 (ApoA1) that consists of SEQ ID NO: 41 in a urine sample from an individual; and (b) Comparing the measurement obtained in (a) to the corresponding value in normal urine, wherein variation in the measurement of (a) compared to the normal urine is indicative of transitional cell carcinoma of the bladder. The method can also determine the stage and severity of the disease.
Patent NZ-567607-A (NZ)
Title: Ceiling-only dry sprinkler systems and methods for addressing a storage occupancy fire
Inventor: GOLINVEAUX JAMES E
IPC: A62C35/00
Filed: 2006-10-23
Abstract: A ceiling-only dry sprinkler system for storage occupancy is disclosed. The storage occupancy defines a ceiling height, a storage configuration, and a defined storage. The system comprises: Àa riser assembly including a control valve having an outlet and an inlet; Àa first network of pipes and a second network of pipes disposed about the riser assembly. The first network of pipes defines a volume containing a gas in communication with the outlet of the control valve. It further includes a plurality of sprinklers having at least one hydraulically remote sprinkler relative to the outlet of the control valve and further having at least one hydraulically close sprinkler relative to the outlet of the control valve. Each of the plurality of sprinklers has a deflector and is thermally rated to thermally trigger from an inactivated state to an activated state to release the gas. The second network of pipes have a wet main in communication with the inlet of the control valve to provide controlled fluid delivery to the first network of pipes; Àa first mandatory fluid delivery delay period defining the time of fluid delivery from the control valve to the at least one hydraulically remote sprinkler; and Àa second mandatory fluid delivery delay period defining the time of fluid delivery from the control valve to the at least one hydraulically close sprinkler.
Patent NZ-575786-A (NZ)
Title: Crystalline forms of thiazolidinedione derivative and its manufacturing method
Inventor: KAJINO HISAKI
IPC: A61K31/427
Filed: 2008-02-08
Abstract: Disclosed is a crystalline form of a hydrate of a dihydrochloride of 5-(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1-H-benzimidazol-2-yl]methoxy}benzyl)-1,3-thiazolidine-2,4-dione represented by the general formula (I), wherein the crystalline form shows main peaks at interplanar spacings of 7.06, 5.79, 5.43, 4.44, 4.18, 3.97, 3.91, 3.68, 3.61, 3.48, 3.24 and 2.97 angstroms in X-ray powder diffraction obtained with Cu K alpha line radiation (wavelength = 1.54 angstroms), or wherein the crystalline form shows main peaks at interplanar spacings of 10.42, 5.85, 5.52, 3.84, 3.46 and 2.95 angstroms in X-ray powder diffraction obtained with Cu K alpha line radiation (wavelength = 1.54 angstroms). A method for preparing the crystalline forms of the above mentioned compound is also disclosed. Also disclosed is the use of the above mentioned crystalline form for the manufacture of a medicament for treating cancer or preventing diabetes.
Patent NZ-577407-A (NZ)
Title: A lie flat pop-up container with unitary gusseted side flaps each interconnecting base and front wall panels, and connected to front wall panel and inturned rear wall extension flaps
Inventor: SEHNERT PERRY ANTHONY
IPC: B65D5/20
Filed: 2010-08-20
Abstract: A lie flat pop-up container is disclosed with unitary gusseted side flaps each interconnecting base and front wall panels, and connected to front wall panel and inturned rear wall extension flaps. The container is formed from a blank and typically has an integral lid.
Patent NZ-578331-A (NZ)
Title: Therapeutical uses of eslicarbazepine
Inventor: SOARES DA SILVA PATRICIO MANUEL VIEIRA ARAUJO
IPC: A61P25/28
Filed: 2008-01-14
Abstract: Disclosed herein is the use of eslicarbazepine or eslicarbazepine acetate in the manufacture of a medicament for treating a condition selected from epilepsy; central and peripheral nervous system disorders; affective disorders; schizoaffective disorders; bipolar disorders; attention disorders; anxiety disorders; neuropathic pain and neuropathic pain-related disorders; sensorimotor disorders; vestibular disorders; and nervous function alterations in degenerative and post-ischemic diseases; in circumstances where the patient to be treated has previously been treated with a medicament that is a substrate for P-glycoprotein or Multiple Resistance Proteins.
Patent NZ-581106-A (NZ)
Title: A Brick
Inventor: PERSON JAMIE
IPC: E04C1/00
Filed: 2009-11-12
Abstract: A brick (10), which is formed as a substantially rectangular block including a pair of generally parallel side walls (11, 12), generally parallel end walls (13, 14), and top and bottom faces (15,16) is disclosed. The brick (10) includes a plurality of cores (17,18,19) that extend through the brick (10) from the top face (15) to the bottom face (16). At least two cores (17) are positioned adjacent each side wall (11, 12) and are spaced apart from each other by at least 5mm. Each core has a pair of spaced apart generally parallel internal walls (20) which are generally parallel to one of the respective side walls (11, 12). The cores (17) further include curved end walls (21) which connect the parallel walls (20). The cores have a cross-sectional area which is greater than 6cm2. The wall thickness between the side walls (11, 12) and the closest parallel internal wall (20) of each core (17) is in the range of between 5mm and 15mm.
Patent NZ-585956-A (NZ)
Title: Pharmaceutical compositions
Inventor: ANDERSSON CARL-MAGNUS
IPC: A61K31/00
Filed: 2008-12-15
Abstract: Disclosed is a pharmaceutical composition suitable for oral administration, comprising an admixture of: (i) a compound of 3-[[3,5-Dibromo-4-(4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyI]-amino]-3-oxopropanoic acid or a pharmaceutically acceptable salt or ester or solvate thereof; (ii) a pharmaceutically acceptable particulate solid which is a Group 1 or Group 2 metal carbonate or bicarbonate. Also disclosed is the use of said composition for the treatment of a disease selected from obesity, hypercholesterolemia, dyslipidemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goitre, thyroid cancer, glaucoma or congestive heart failure and a method to prepare said composition.